Although the mechanisms to explain why LPS was markedly higher in the CON trial—and appear attenuated in the CP trial—are not obvious from our results, the potential benefits for athletes but especially clinical populations of neutralising LPS are significant, and therefore future research should explore whether CP has a role in attenuating endotoxemia. This evidence concerns the gene CP and serum lipopolysaccharide activity.